Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Mol Cancer Ther. 2019 Mar 29;18(5):1012–1021. doi: 10.1158/1535-7163.MCT-18-1103

Figure 3. Addition of Ascorbic Acid to Drug Preparation.

Figure 3.

Figure 3 shows radio HPLC and biodistribution studies of 212Pb-DOTAMTATE with ascorbic acid. A. Radio-HPLC of 212Pb-DOTAMTATE without ascorbic acid present during chelation (orange) or with 10mM final concentration of ascorbic acid (blue) prior to biodistribution. B. Biodistribution of 212Pb-DOTAMTATE in AR42J tumor bearing mice (n=5 per group) at 1hr, 4hr and 24hrs post drug injection in the presence of 10mM ascorbic acid (blue) or none (orange).